摘要
目的观察玻璃体腔内注射康柏西普联合激光治疗视网膜中央静脉阻塞继发黄斑水肿的临床疗效。方法收集2015年3月至2016年3月潍坊医学院附属医院确诊的视网膜中央静脉阻塞患者50例50只眼,随机分成康柏西普联合激光治疗组(C+L组)和激光治疗组(L组),每组25例25眼。C+L组玻璃体腔内注射康柏西普,1周后再行视网膜激光光凝术;L组直接行视网膜激光光凝术。记录治疗前以及治疗后1周、1月、3月患者的最佳较正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)的变化。结果 C+L组患者在1周、1月及3月随诊中BCVA提升显著优于L组,差异均具有统计学意义(P<0.05)。两组在治疗后1周、1月、3月与治疗前相比平均CMT明显下降,差异具有统计学意义(P<0.05)。C+L组患者在治疗后1周、1月及3月时间节点随诊中平均CMT显著优于L组,差异均具有统计学意义(P<0.05)。结论玻璃体腔内注射康柏西普联合视网膜激光光凝能够安全、有效地治疗视网膜中央静脉阻塞继发的黄斑水肿。
Objective To observe the clinical effect of intravitreal injection of Conbercept combined with retinal laser treatment for macular edema caused by central retinal vein occlusion.Methods A total of 50 eyes of 50 patients with central retinal vein,diagnosed in Affiliated Hospital of Weifang Medical College from March 2015 to March 2016,were divided into two groups randomly.Conbercept combined laser treatment group（C＋L）25cases 25 eyes,were given retinal laser photocoagulation after intravitreal injection of Conbercept 1week later.Laser treatment group（L）25cases 25 eyes underwent retinal laser photocoagulation only.The best corrected visual acuity（BCVA）and central macular thickness（CMT）changes were checked in patients before treatment and after 1week,1month and 3months of treatment.Results The patients of the C＋L group,in 1week,1month and 3months were followed up,the BCVA was superior to the L group significantly,and there was significant difference（P〈0.05）.After 1week,1month and 3months of treatment,the average CMT of both groups were significantly decreased compared with before,and there was significant difference（P〈0.05）.The average CMT in C＋L group was better than L group after 1week,1month and 3months of treatment,and there was significant difference（P〈0.05）.ConclusionIntravitreal injection of Conbercept combined with retinal laser photocoagulation is a safety and effective method for macular edema caused by central retinal vein occlusion.
出处
《青岛医药卫生》
2017年第2期81-83,共3页
Qingdao Medical Journal
